Loading organizations...
§ Private Profile · Hayward, CA, USA
Clinical-stage biopharmaceutical company developing cancer immunotherapies and targeted oncology drugs, focused on immuno-oncology.
Arcus Biosciences is a clinical-stage biopharmaceutical company developing cancer immunotherapies and targeted oncology drugs, based in Hayward, California. The publicly traded enterprise employs over 500 people and has advanced six distinct molecules into clinical development, including two candidates currently undergoing Phase III trials for non-small cell lung cancer. Prior to its 2018 initial public offering on the New York Stock Exchange, the firm raised approximately $120 million in early-stage venture capital funding. Its research and development pipeline is supported by strategic partnerships and financial investments from recognizable entities such as Gilead Sciences, GV, ARCH Venture Partners, and Taiho Pharmaceutical. Notably, Gilead Sciences expanded its collaboration with the business in early 2024 through a $320 million equity investment to accelerate joint immuno-oncology programs. Arcus Biosciences was founded in 2015 by Terry Rosen and Juan Jaen.
Arcus Biosciences has raised $497.0M across 3 funding rounds.
Arcus Biosciences has raised $497.0M in total across 3 funding rounds.
Arcus Biosciences has raised $497.0M across 3 funding rounds. Most recently, it raised $320.0M Other Equity in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 30, 2024 | $320M Venture Round | Merdad Parsey | — | Announced |
| Nov 13, 2017 | $107M Series C | GV | Aisling Capital, BVF Partners, Celgene, Decheng Capital, Droia Ventures, EcoR1 Capital, Foresite Capital, Hillhouse Capital Group, Invus Opportunities, Leerink Partners, Taiho Ventures, The Column Group, Wellington Management | Announced |
| Sep 1, 2016 | $70M Series B | — | Celgene, Droia Ventures, Foresite Capital, GV, Invus, Novartis, Stanford University, Taiho Ventures, The Column Group | Announced |
Arcus Biosciences has raised $497.0M in total across 3 funding rounds.
Arcus Biosciences's investors include Merdad Parsey, Google Ventures, Aisling Capital, BVF Partners, Celgene, Decheng Capital, Droia Ventures, EcoR1 Capital, Foresite Capital, Hillhouse Capital Group, Invus Opportunities, Leerink Partners.